Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 18, 2007

Vegenics Licenses Antibodies from CoGenesys

  • Vegenics licensed from CoGenesys exclusive, worldwide rights to human mAbs that target vascular endothelial growth factor-C (VEGF-C). VEGF-C is believed to play an important role in promoting the formation of new blood vessels and the maintenance of existing blood vessels.

    "Our partnership with Vegenics is a great example of our business model, in which multiple, early-stage partnering agreements will generate a continuing revenue stream to support our own internal development activities," says Mark Rampy, CBO of CoGenesys.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »